Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study

被引:31
|
作者
Wilson, Gregory C. [1 ]
Maithel, Shishir K. [2 ]
Bentrem, David [6 ]
Abbott, Daniel E. [7 ]
Weber, Sharon [7 ]
Cho, Clifford [7 ]
Martin, Robert C. G. [3 ]
Scoggins, Charles R. [3 ]
Kim, Hong Jin [4 ]
Merchant, Nipun B. [5 ]
Kooby, David A. [2 ]
Edwards, Michael J. [1 ]
Ahmad, Syed A. [1 ]
机构
[1] Univ Cincinnati, Med Ctr, Dept Surg, Div Surg Oncol, Cincinnati, OH 45267 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Louisville, Louisville, KY 40292 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Univ Miami, Miami, FL USA
[6] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA
[7] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
关键词
INTERNATIONAL-CONSENSUS-GUIDELINES; CYSTIC NEOPLASMS; TREATED PATIENTS; SENDAI; ASSOCIATION; EXPERIENCE; RISK; SIZE; IPMN;
D O I
10.1016/j.jamcollsurg.2016.12.031
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Controversy persists regarding the management of patients with intraductal papillary mucinous neoplasms (IPMN). International consensus guidelines stratify patients into high-risk, worrisome, and low risk categories. STUDY DESIGN: The medical records of 7 institutions were reviewed for patients who underwent surgical management of IPMN between 2000 and 2015. RESULTS: There were 324 patients included in the analysis; 60.4% of patients had main-duct/mixed type, and 39.7% had branch-duct IPMN. The median cyst size was 2.65 cm, invasive cancer (IC) or high-grade dysplasia (HGD) was present in 42% (n = 136); 68.9% of patients with high-risk, 40.0% of patients with worrisome, and 24.6% of patients with low risk features exhibited HGD/IC. Multivariate analysis demonstrated that only 1 of 3 high-risk features and 2 of 7 worrisome features predicted the presence ofHGD/IC. Positive predictive values for HGD/IC in patients with obstructive jaundice and lymphadenopathy were 0.83 (95% CI 0.65 to 0.94) and 0.69 (95% CI 0.39 to 0.91), respectively. In the absence of high-risk features, HGD/IC was still present in 57.4% of patients with 2 or more worrisome features. Regression analysis demonstrated that each additional worrisome factor present was additive in predicting HGD/IC in a linear fashion (odds ratio 1.39; 95% CI 1.08 to 1.80; p < 0.01). CONCLUSIONS: These data demonstrate that the current consensus guidelines for surgical resection of IPMN may not adequately stratify and identify patients at risk for having HGD or invasive cancer. Patients with multiple worrisome features, in the absence of high-risk factors, should be considered for resection. (C) 2017 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:461 / 469
页数:9
相关论文
共 50 条
  • [1] Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study Discussion
    Wolfgang, Christopher
    Tyler, Douglas
    Lillemoe, Keith
    Cameron, John
    Ahmad, Syed
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 224 (04) : 469 - 472
  • [2] Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms? A Multi-institutional Study
    Dhar, Vikrom K.
    Merchant, Nipun B.
    Patel, Sameer H.
    Edwards, Michael J.
    Wima, Koffi
    Imbus, Joseph
    Abbott, Daniel E.
    Weber, Sharon M.
    Louie, Raphael
    Kim, Hong J.
    Martin, Robert C. G.
    Scoggins, Charles R.
    Bentrem, David J.
    LeCompte, Michael T.
    Idrees, Kamran
    Lopez-Aguiar, Alexandra G.
    Maithel, Shishir K.
    Kooby, David A.
    Franco, Daniel A.
    Yakoub, Danny
    Ahmad, Syed A.
    ANNALS OF SURGERY, 2018, 268 (03) : 469 - 478
  • [3] International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas
    Tanaka, Masao
    Chari, Suresh
    Adsay, Volkan
    Fernandez-del Castillo, Carlos
    Falconi, Massimo
    Shimizu, Michio
    Yamaguchi, Koji
    Yamao, Kenji
    Matsuno, Seiki
    PANCREATOLOGY, 2006, 6 (1-2) : 17 - 32
  • [4] Management of intraductal papillary mucinous neoplasms of the pancreas
    Perez-Johnston, R.
    Lin J, D.
    Carlos, C. Fernandez-Del Castillo
    Sahani, D.
    MINERVA CHIRURGICA, 2009, 64 (05) : 477 - 487
  • [5] The management of intraductal papillary mucinous neoplasms of the pancreas
    Pollini, Tommaso
    Andrianello, Stefano
    Caravati, Andrea
    Perri, Giampaolo
    Malleo, Giuseppe
    Paiella, Salvatore
    Marchegiani, Giovanni
    Salvia, Roberto
    MINERVA CHIRURGICA, 2019, 74 (05) : 414 - 421
  • [6] The Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Allen, Peter J.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (02) : 297 - +
  • [7] Surgical Outcome of Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Toshio Nakagohri
    Taira Kinoshita
    Masaru Konishi
    Shinichiro Takahashi
    Naoto Gotohda
    Annals of Surgical Oncology, 2007, 14 : 3174 - 3180
  • [8] Intraductal papillary mucinous neoplasms of the pancreas—a surgical disease
    Jens Werner
    Stefan Fritz
    Markus W. Büchler
    Nature Reviews Gastroenterology & Hepatology, 2012, 9 : 253 - 259
  • [9] Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas
    Seiko Hirono
    Hiroki Yamaue
    Surgery Today, 2020, 50 : 50 - 55
  • [10] Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas
    Hirono, Seiko
    Yamaue, Hiroki
    SURGERY TODAY, 2020, 50 (01) : 50 - 55